Systemic Endotoxin in Peritoneal Dialysis Patients

Area of Science:

• Nephrology
• Clinical Chemistry
• Microbiology

Background:

• Systemic endotoxemia is linked to inflammation, cardiovascular disease, and mortality in dialysis patients.
• Peritoneal dialysis (PD) patients often use acidic dialysates, potentially increasing gut permeability and endotoxemia.
• Existing studies on endotoxin levels in PD patients show conflicting results.

Purpose of the Study:

• To measure systemic endotoxin levels in peritoneal dialysis (PD) outpatients.
• To investigate associations between endotoxin levels and patient characteristics, inflammation markers, and PD parameters.
• To explore factors contributing to discordant results in previous endotoxin measurements.

Main Methods:

• Systemic endotoxin was measured in 55 PD outpatients during routine assessments.
• Patient demographics, medical history (including diabetes), PD treatment details (dialysate composition, duration), and medications were recorded.
• Measurements included markers of inflammation, serum albumin, N-terminal pro-brain natriuretic peptide, and extracellular volume via bioimpedance.

Main Results:

• The median systemic endotoxin concentration was 0.0485 Eu/mL.
• No significant associations were found between endotoxin levels and patient demographics, inflammation markers, albumin, NT-proBNP, extracellular volume, blood pressure, PD prescriptions, membrane transporter status, or medications.
• Factors such as assay methodology, sample contamination, and failure to release protein-bound endotoxin can influence measurement variability.

Conclusions:

• Standard peritoneal dialysis dialysates do not appear to significantly increase systemic endotoxin levels.
• Methodological challenges in endotoxin measurement, including differentiating free and bound endotoxin, contribute to inconsistent findings.
• The precise role of endotoxin in causing inflammation among PD patients remains undetermined pending improved assay standardization.